347 related articles for article (PubMed ID: 26655835)
1. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Guo X; Wang X; Wang Z; Banerjee S; Yang J; Huang L; Dixon JE
Nat Cell Biol; 2016 Feb; 18(2):202-12. PubMed ID: 26655835
[TBL] [Abstract][Full Text] [Related]
2. Ramping up degradation for proliferation.
Huibregtse JM; Matouschek A
Nat Cell Biol; 2016 Feb; 18(2):141-2. PubMed ID: 26820437
[TBL] [Abstract][Full Text] [Related]
3. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Banerjee S; Ji C; Mayfield JE; Goel A; Xiao J; Dixon JE; Guo X
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8155-8160. PubMed ID: 29987021
[TBL] [Abstract][Full Text] [Related]
4. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Banerjee S; Wei T; Wang J; Lee JJ; Gutierrez HL; Chapman O; Wiley SE; Mayfield JE; Tandon V; Juarez EF; Chavez L; Liang R; Sah RL; Costello C; Mesirov JP; de la Vega L; Cooper KL; Dixon JE; Xiao J; Lei X
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24881-24891. PubMed ID: 31754034
[TBL] [Abstract][Full Text] [Related]
6. Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function.
Liu X; Xiao W; Zhang Y; Wiley SE; Zuo T; Zheng Y; Chen N; Chen L; Wang X; Zheng Y; Huang L; Lin S; Murphy AN; Dixon JE; Xu P; Guo X
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):328-336. PubMed ID: 31843888
[TBL] [Abstract][Full Text] [Related]
7. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
[TBL] [Abstract][Full Text] [Related]
8. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Regulation of Proteasome Function by Subunit Phosphorylation.
VerPlank JJS; Goldberg AL
Methods Mol Biol; 2018; 1844():309-319. PubMed ID: 30242718
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.
Pereg Y; Liu BY; O'Rourke KM; Sagolla M; Dey A; Komuves L; French DM; Dixit VM
Nat Cell Biol; 2010 Apr; 12(4):400-6. PubMed ID: 20228808
[TBL] [Abstract][Full Text] [Related]
11. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
[TBL] [Abstract][Full Text] [Related]
12. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.
Hu MC; Lee DF; Xia W; Golfman LS; Ou-Yang F; Yang JY; Zou Y; Bao S; Hanada N; Saso H; Kobayashi R; Hung MC
Cell; 2004 Apr; 117(2):225-37. PubMed ID: 15084260
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
14. Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Wang Y; Wu Y; Miao X; Zhu X; Miao X; He Y; Zhong F; Ding L; Liu J; Tang J; Huang Y; Xu X; He S
Int J Biol Macromol; 2015 Nov; 81():809-17. PubMed ID: 26341817
[TBL] [Abstract][Full Text] [Related]
15. Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Mimoto R; Imawari Y; Hirooka S; Takeyama H; Yoshida K
Oncogene; 2017 Mar; 36(13):1862-1872. PubMed ID: 27721402
[TBL] [Abstract][Full Text] [Related]
16. PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation.
Kang SA; Lee ST
Biochem Biophys Res Commun; 2013 Feb; 431(4):734-9. PubMed ID: 23352614
[TBL] [Abstract][Full Text] [Related]
17. Regulating protein breakdown through proteasome phosphorylation.
VerPlank JJS; Goldberg AL
Biochem J; 2017 Sep; 474(19):3355-3371. PubMed ID: 28947610
[TBL] [Abstract][Full Text] [Related]
18. DYRK1A stabilizes HPV16E7 oncoprotein through phosphorylation of the threonine 5 and threonine 7 residues.
Liang YJ; Chang HS; Wang CY; Yu WC
Int J Biochem Cell Biol; 2008; 40(11):2431-41. PubMed ID: 18468476
[TBL] [Abstract][Full Text] [Related]
19. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis.
Lee M; Oprea-Ilies G; Saavedra HI
Oncotarget; 2015 Nov; 6(35):37316-34. PubMed ID: 26512919
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.
Zu Y; Liu L; Lee MY; Xu C; Liang Y; Man RY; Vanhoutte PM; Wang Y
Circ Res; 2010 Apr; 106(8):1384-93. PubMed ID: 20203304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
